AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37964240 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) added to usual case management (UC)
Number of subjects: 514
Study 37964240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified Vocational Advice Intervention (SVAI) added to usual case management (UC)
Number of subjects: 514
Study 37964240 — intervention group
Group type: COMPARATOR
Intervention: Usual Case Management (UC)
Number of subjects: 514
Study 37964252 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyKind programme (four lesson, school-based, teacher led, universal body image programme)
Number of subjects: 600
Study 37964252 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyKind programme
Number of subjects: 600
Study 37964259 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 108
Study 37964300 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality exposure scenarios (neutral, living room, bar)
Number of subjects: 60
Study 37964330 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based diabetes management package (DMP) including access to an app, health coaching, pedometer, glucometer, weighing scale, with or without M-POWER rewards scheme
Number of subjects: 0
Study 37964330 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37964367 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized TEACH-PD training curriculum
Number of subjects: 42
Study 37964367 — intervention group
Group type: COMPARATOR
Intervention: Usual training practice
Number of subjects: 42
Study 37964379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist), and nivolumab (anti-PD-1)
Number of subjects: 13
Study 37964379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of anti-CSF1R in murine models
Number of subjects: 13
Study 37964379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prolonged stable disease or partial response
Number of subjects: 13
Study 37964431 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mg nicotine concentration ONP
Number of subjects: 30
Study 37964431 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mg nicotine concentration ONP
Number of subjects: 30
Study 37964431 — intervention group
Group type: COMPARATOR
Intervention: usual brand cigarette
Number of subjects: 30
Study 37964515 — intervention group
Group type: EXPERIMENTAL
Intervention: Median approach to SESPB
Number of subjects: 4
Study 37964515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate approach to SESPB
Number of subjects: 4
Study 37964784 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT intervention (multidisciplinary approach including predischarge education and coordinated postdischarge follow-up)
Number of subjects: 46
Study 37964784 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (part of ACT intervention)
Number of subjects: 46
Study 37964784 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (control)
Number of subjects: 46
Study 37964784 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT group (part of ACT intervention)
Number of subjects: 46
Study 37965170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 6004
Study 37965169 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological-behavioral intervention (CoRE) consisting of six individual and two group sessions led by a certified psychologist.
Number of subjects: 0
Study 37965169 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (not receiving the intervention).
Number of subjects: 0
Study 37965250 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the Holy Quran recital for 10 minutes twice daily
Number of subjects: 132
Study 37965250 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study 37965307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on nine TME-related genes (TMRGs): C3orf62, DPYSL2, GZMA, SERPINB3, RHCG, PTPRR, STMN3, TMPRSS4, COMP.
Number of subjects: 0
Study 37965307 — intervention group
Group type: EXPERIMENTAL
Intervention: TMEscore for overall survival (OS) prediction.
Number of subjects: 0
Study 37965307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group characteristics.
Number of subjects: 0
Study 37965307 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TMEscore with drug susceptibility and immune cell infiltration.
Number of subjects: 0
Study 37965307 — intervention group
Group type: EXPERIMENTAL
Intervention: SERPINB3 gene expression.
Number of subjects: 0
Study 37965339 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell product specific for CMV and EBV, administered on day +30, total of 25 doses
Number of subjects: 9
Study 37965339 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 9
Study 37965347 — intervention group
Group type: EXPERIMENTAL
Intervention: ConA plus standard of care (SOC)
Number of subjects: 84
Study 37965347 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 84
Study 37965376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (n=17)
Number of subjects: 33
Study 37965376 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n=16)
Number of subjects: 33
Study 37965431 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 272
Study 37965431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 37965466 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam therapy (PBT)
Number of subjects: 99
Study 37965466 — intervention group
Group type: COMPARATOR
Intervention: Photon-based radiation therapy (XRT)
Number of subjects: 99
Study 37965628 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PCR-based approach for quantifying donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 52
Study 37965628 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples collected coincidentally to biopsies
Number of subjects: 52
Study 37965767 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (LPD)
Number of subjects: 656
Study 37965767 — intervention group
Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 656
Study 37965771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine added to spinal anesthesia
Number of subjects: 0
Study 37965771 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia without epinephrine (implied control)
Number of subjects: 0
Study 37965944 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus no treatment
Number of subjects: 2888
Study 37965944 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus watchful waiting
Number of subjects: 2888
Study 37965944 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus non-surgical treatment (antibiotics)
Number of subjects: 2888
Study 37965944 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes (VTs) versus myringotomy
Number of subjects: 2888
Study 37966076 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ostomy education intervention
Number of subjects: 138
Study 37966076 — intervention group
Group type: COMPARATOR
Intervention: Postoperative education
Number of subjects: 138
Study 37966080 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-hole drainage zone catheter
Number of subjects: 60
Study 37966080 — intervention group
Group type: COMPARATOR
Intervention: Conventional eyelet catheter (CEC)
Number of subjects: 60
Study 37966286 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-stimulated copeptin
Number of subjects: 158
Study 37966286 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline-stimulated copeptin
Number of subjects: 158
Study 37966285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 1965
Study 37966285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1965
Study 37966313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and Emotional Responses to COPD Exacerbations
Number of subjects: 0
Study 37966313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of Care Seeking
Number of subjects: 0
Study 37966670 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant
Number of subjects: 4956
Study 37966670 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cancer
Number of subjects: 4956
Study 37966670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung or metastatic cancer
Number of subjects: 4956
Study 37966670 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain, hematological or gastrointestinal cancer
Number of subjects: 4956
Study 37966676 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour empowerment self-defense (ESD) intervention
Number of subjects: 3263
Study 37966676 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (2-hour intervention)
Number of subjects: 3263
Study 37966817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 441
Study 37966817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 37966840 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care)
Number of subjects: 248
Study 37966840 — intervention group
Group type: COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Number of subjects: 248
Study 37966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1174
Study 37966841 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1174
Study 37966877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention 'Olitor' (app usage at least weekly for 3 months)
Number of subjects: 15
Study 37966877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention 'Olitor'
Number of subjects: 15
Study 37966877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 37967050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy customized for visual symptoms (MBCT-vision)
Number of subjects: 21
Study 37967058 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door delivery of oral azithromycin
Number of subjects: 80
Study 37967058 — intervention group
Group type: COMPARATOR
Intervention: Fixed-point delivery of oral azithromycin
Number of subjects: 80
Study 37967058 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door delivery
Number of subjects: 80
Study 37967058 — intervention group
Group type: COMPARATOR
Intervention: Fixed-point delivery
Number of subjects: 80
Study 37967058 — intervention group
Group type: COMPARATOR
Intervention: Both delivery methods
Number of subjects: 80
Study 37967136 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9574
Number of subjects: 0
Study 37967136 — intervention group
Group type: COMPARATOR
Intervention: AZD9574 + TMZ
Number of subjects: 0
Study 37967136 — intervention group
Group type: COMPARATOR
Intervention: TMZ
Number of subjects: 0
Study 37967148 — intervention group
Group type: EXPERIMENTAL
Intervention: KCONVAC vaccine (2 doses, 28 days apart)
Number of subjects: 564
Study 37967148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 37967228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 23
Study 37967326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose rVSVΔG-ZEBOV-GP
Number of subjects: 1602
Study 37967326 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56)
Number of subjects: 1602
Study 37967326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study 37967350 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 37967392 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction and Pressure to Eat
Number of subjects: 0
Study 37967471 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection in ITP patients
Number of subjects: 1148
Study 37967565 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (Parental Psychoeducation in CHD [PPeCHD]) and usual routines
Number of subjects: 28
Study 37967565 — intervention group
Group type: COMPARATOR
Intervention: Regular practices (control group)
Number of subjects: 28
Study 37967641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist e-consult
Number of subjects: 466
Study 37967641 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norming dashboards
Number of subjects: 466
Study 37967641 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study 37967828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic quantitative sensory testing
Number of subjects: 0
Study 37968000 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient data meta-analysis (IPD-MA)
Number of subjects: 0
Study 37968000 — intervention group
Group type: COMPARATOR
Intervention: Existing PSE prediction models
Number of subjects: 0
Study 37968003 — intervention group
Group type: EXPERIMENTAL
Intervention: moderate-intensity aerobic physical activity for 150 min/week
Number of subjects: 130
Study 37968012 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole intravenously daily while mechanically ventilated in the ICU
Number of subjects: 0
Study 37968012 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo daily while mechanically ventilated in the ICU
Number of subjects: 0
Study 37968015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 2228
Study 37968015 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting tricuspid annular plane systolic excursion to systolic pulmonary artery pressure <0.7 mm/mm Hg
Number of subjects: 2228
Study 37968015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure-cardiac output >5 mm Hg.min/L
Number of subjects: 2228
Study 37968019 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy
Number of subjects: 457
Study 37968019 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (optimal medical therapy)
Number of subjects: 457
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index (AHI)
Number of subjects: 186
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of recording time with oxygen saturation <90% (T90)
Number of subjects: 186
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: T90
Number of subjects: 186
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: T90 in non-CTD-associated PAH
Number of subjects: 186
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: T90 in CTD-associated PAH
Number of subjects: 186
Study 37968017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-related hypoxia
Number of subjects: 186
Study 37968125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target of 110 mmHg to <130 mmHg)
Number of subjects: 8511
Study 37968125 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP target of 130 mmHg to <150 mmHg)
Number of subjects: 8511
Study 37968125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 8511
Study 37968125 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 8511
Study 37968132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin (0.5 µg/kg, three times weekly)
Number of subjects: 222
Study 37968132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 37968170 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney BEAM physical activity digital health intervention
Number of subjects: 340
Study 37968170 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 340
Study 37968194 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 37968194 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37968287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) monitoring
Number of subjects: 1565
Study 37968287 — intervention group
Group type: COMPARATOR
Intervention: Arterial waveform-based monitoring (FloTrac-Vigileo)
Number of subjects: 1565
Study 37968455 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers treatment
Number of subjects: 454
Study 37968455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol consumption
Number of subjects: 454
Study 37968455 — intervention group
Group type: EXPERIMENTAL
Intervention: High BPV
Number of subjects: 454
Study 37968455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 454
Study 37968455 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 454
Study 37968547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 0
Study 37968547 — intervention group
Group type: COMPARATOR
Intervention: Standard tidal volume ventilation
Number of subjects: 0
Study 37968668 — intervention group
Group type: EXPERIMENTAL
Intervention: MenSC therapy (bilateral intraovarian injection of menstrual blood-derived mesenchymal stromal cells)
Number of subjects: 180
Study 37968668 — intervention group
Group type: EXPERIMENTAL
Intervention: MenSC therapy
Number of subjects: 180
Study 37968668 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 180
Study 37968689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 764
Study 37968689 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional care
Number of subjects: 764
Study 37968696 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-biopsy anti-HER2 treatment
Number of subjects: 700
Study 37968696 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-driven expression profile
Number of subjects: 700
Study 37968696 — intervention group
Group type: COMPARATOR
Intervention: Prior anti-HER2 treatment
Number of subjects: 700
Study 37968718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 immunotherapy
Number of subjects: 0
Study 37968738 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration deep breathing (SDDB) + Conventional physiotherapy (CP)
Number of subjects: 30
Study 37968738 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 30
Study 37968741 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose AZI (biannual azithromycin-MDA)
Number of subjects: 1
Study 37968741 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose AZI (quarterly azithromycin-MDA)
Number of subjects: 1
Study 37968741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1
Study 37969014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide and Emtricitabine (TAF/FTC)
Number of subjects: 0
Study 37969014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming palpation (WP)
Number of subjects: 152
Study 37969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming ultrasonography-guided (WU)
Number of subjects: 152
Study 37969298 — intervention group
Group type: COMPARATOR
Intervention: Non-warming palpation (NP)
Number of subjects: 152
Study 37969298 — intervention group
Group type: COMPARATOR
Intervention: Non-warming ultrasonography-guided (NU)
Number of subjects: 152
Study 37969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming groups (WP + WU)
Number of subjects: 152
Study 37969395 — intervention group
Group type: EXPERIMENTAL
Intervention: apatinib (375 mg, orally, once daily)
Number of subjects: 54
Study 37969395 — intervention group
Group type: EXPERIMENTAL
Intervention: apatinib (375 mg, orally, once daily) plus etoposide (50 mg, orally on days 1-14 of each 21-day cycle)
Number of subjects: 54
Study 37969640 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor blocker (atrasentan)
Number of subjects: 28
Study 37969640 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer patients (before chemotherapy)
Number of subjects: 28
Study 37969646 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 711
Study 37969646 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT and hs-cTnI algorithms
Number of subjects: 711
Study 37969655 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) reported using the Godin-Shephard LTPA questionnaire
Number of subjects: 223
Study 37969655 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 223
Study 37969655 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased LTPA over the 3 months
Number of subjects: 223
Study 37969655 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient LTPA according to PA guidelines
Number of subjects: 223
Study 37969929 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV
Number of subjects: 287
Study 37969929 — intervention group
Group type: COMPARATOR
Intervention: TAV
Number of subjects: 287
Study 37969936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600 IU daily for 14-16 weeks)
Number of subjects: 498
Study 37969936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 capsule daily for 14-16 weeks)
Number of subjects: 498
Study 37969958 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 152
Study 37969958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 37970718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gruticibart (anti-FXI mAb) 2 mg/kg administered through the venous catheter within 24 hours of placement
Number of subjects: 22
Study 37970718 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninterventional study)
Number of subjects: 22
Study 37970718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gruticibart (anti-FXI mAb)
Number of subjects: 22